Free Trial
→ Trump’s Top Secret $9 Trillion AI Superweapon (From Brownstone Research) (Ad)

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apexigen, Inc. stock logo
APGN
Apexigen
$0.39
$0.39
$0.33
▼
$8.28
$9.57M3.6967,731 shsN/A
EFHTU
EF Hutton Acquisition Co. I
$10.10
-1.9%		$10.10
$9.95
▼
$11.33
N/AN/A99,600 shs800 shs
These 7 Stocks Will Be Magnificent in 2025 Cover
These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apexigen, Inc. stock logo
APGN
Apexigen
0.00%0.00%0.00%0.00%0.00%
EFHTU
EF Hutton Acquisition Co. I
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apexigen, Inc. stock logo
APGN
Apexigen
N/AN/AN/AN/AN/AN/AN/AN/A
EFHTU
EF Hutton Acquisition Co. I
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apexigen, Inc. stock logo
APGN
Apexigen
0.00
N/AN/AN/A
EFHTU
EF Hutton Acquisition Co. I
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apexigen, Inc. stock logo
APGN
Apexigen
N/AN/AN/AN/A($0.09) per shareN/A
EFHTU
EF Hutton Acquisition Co. I
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apexigen, Inc. stock logo
APGN
Apexigen
-$32.07MN/A0.00∞N/AN/A-614.82%-133.30%N/A
EFHTU
EF Hutton Acquisition Co. I
N/AN/A0.00∞N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apexigen, Inc. stock logo
APGN
Apexigen
N/AN/AN/AN/AN/A
EFHTU
EF Hutton Acquisition Co. I
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apexigen, Inc. stock logo
APGN
Apexigen
N/A
0.82
0.82
EFHTU
EF Hutton Acquisition Co. I
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Apexigen, Inc. stock logo
APGN
Apexigen
13.65%
EFHTU
EF Hutton Acquisition Co. I
N/A

Insider Ownership

CompanyInsider Ownership
Apexigen, Inc. stock logo
APGN
Apexigen
19.20%
EFHTU
EF Hutton Acquisition Co. I
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Apexigen, Inc. stock logo
APGN
Apexigen
1124.86 million20.09 millionNot Optionable
EFHTU
EF Hutton Acquisition Co. I
N/AN/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com
Apexigen stock logo

Apexigen NASDAQ:APGN

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

EF Hutton Acquisition Co. I NASDAQ:EFHTU

EF Hutton Acquisition Corporation I offers effecting a merger, stock capital exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the consumer and retail industry. The company was founded in 2022 and is based in Hingham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas